22nd Jan 2014 10:27
LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it had received a patent from the US Patent and Trademark Office for one of the inventions associated to its CHK1 cancer treatment programme.
The patent covers compounds developed by Sareum and Cancer Research UK-funded scientists that inhibit the function of CHK1 enzymes to potentially treat cancer.
The CHK1 programme is being progressed towards clinical trials by the Cancer Research Technology Pioneer Fund, Sareum and BACIT Ltd.
Sareum noted that this patent has limited territorial coverage, but is part of a wider group of pending patents which would provide broader geographical protection for the programme.
"Consistent with the usual business of the company, the intellectual property estate that underpins the CHK1 programme continues to develop, protecting the asset and enhancing its commercial value," said Chief Executive Officer Tim Mitchell in a statement.
Shares in Sareum were trading down 1.0% at 0.668 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum